araag2/HINT huggingface dataset:
Clinical trial NCT01225302 (phase 1, status: completed)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: linifanib, linifanib, carboplatin, paclitaxel
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        Inclusion Criteria

          -  The subject must be 20 and older years of age.

          -  The subject must have cytologically or histologically confirmed non-squamous NSCLC.
             Subjects may have a mixed histology but must be predominantly non-squamous to be
             eligible.

          -  The subject must have advanced or metastatic (Stage IV [According to American Joint
             Committee on Cancer (AJCC) staging manual, 7th edition]) disease that is not amenable
             to surgical resection or radiation with curative intent.

          -  The subject must have not received prior chemotherapy for NSCLC.

          -  The subject has measurable disease, defined as at least 1 unidimensionally measurable
             lesion on a CT scan as defined by Response Evaluation Criteria in Solid Tumors
             (RECIST) Version 1.1.

          -  The subject has an Easter Cooperative Oncology Group (ECOG) Performance Score of 0-1.

          -  The subject must have adequate bone marrow, renal and hepatic function.

        Exclusion Criteria

          -  The subject has hypersensitivity to paclitaxel or to other drugs formulated with
             polyethoxylated castor oil (Cremophor).

          -  The subject has received any anti-cancer therapy for treatment of NSCLC including
             investigational agents, immunotherapy, traditional Chinese medicine/herbal remedies,
             hormonal, "targeted" agents (i.e., erlotinib, imatinib), biologic therapy or cytotoxic
             chemotherapy (i.e., alkylating agents, microtubule inhibitors, antimetabolites).

          -  The subject has a history of another active cancer within the past 5 years except
             cervical cancer in situ, in situ carcinoma of the bladder, squamous cell or basal cell
             carcinoma of the skin.

          -  The subject has active ulcerative colitis, Crohn's disease, celiac disease or any
             other conditions that interfere with absorption.

          -  The subject has a medical condition, which in the opinion of the study investigator
             places them at an unacceptably high risk for toxicities.

          -  The subject is pregnant or breast feeding.

          -  The subject has NSCLC with a predominant squamous cell histology.
Clinical trial NCT00634504 (phase 1, status: completed)
Conditions: osteosarcoma, leukemia, lymphoma
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: glucarpidase, high-dose methotrexate, leucovorin, high-dose methotrexate, leucovorin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Receiving High-dose methotrexate (HDMTX) with or without risk of methotrexate (MTX)
             toxicity, impaired renal function, and delayed MTX elimination

          -  Require intravenous leucovorin

        Exclusion Criteria:

          -  Arm A only: allergic reactions to lactose

          -  Arm A only: hereditary fructose or galactose intolerance

          -  Arm B only: delayed elimination of MTX
Clinical trial NCT00556400 (phase 1/phase 2, status: terminated)
Conditions: aplastic anemia, menorrhagia, amenorrhea
ICD codes: D61.3, D61.9, D61.09, D61.1, D61.2, D61.89, N91.0, N91.1, N91.2
Drugs: lo-ovral oral contraceptive pills, placebo - sugar pill
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    early termination because of insufficient accrual.
  
Eligibility criteria:

        -  INCLUSION CRITERIA:

        Women aged 12-55 years who have a uterus and at least one functioning ovary.

        Women with any active uterine bleeding more than spotting

        Diagnosed with bone marrow failure, and other disease that require treatment with
        chemotherapy or stem cell transplantation with platelet counts less than 50,000 microliters
        at study entry

        Do not desire pregnancy for the duration of the study.

        Willing and able to give informed consent.

        Willing and able to comply with study requirements.

        EXCLUSION CRITERIA:

        Age less than 12 years

        Postmenopausal women

        Hormone level in menopausal range: Follicle Stimulating Hormone greater than 40 IU/L, E (2)
        less than 20 pg/ml

        History of liver disease that precludes OCP use

        History of thrombosis, thromboembolism and/or thrombophilia.

        Currently on 2 or more tablets of any oral contraceptive pills per day at study entry

        Having 2 or more depo medroxyprogesterone acetate injections in the past 12 months or
        having depo medroxyprogesterone acetate injection in the past 90 days

        Leuprolide acetate injection in the past 30 days

        Smoker over the age of 35

        Women with estrogen dependent tumor e.g. breast cancer.

        Pregnancy.

        Underlying sickle cell anemia

        Women who are taking chemotherapeutic agents known to cause ovarian failure such as
        alkylating agents

        Allergy to any medication in this protocol
Clinical trial NCT00401401 (phase 1/phase 2, status: terminated)
Conditions: head and neck cancer, squamous cell cancer
ICD codes: C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11, C96.20, C96.29, D47.09
Drugs: zalutumumab, cisplatin
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Reason stopped: 
    mtd was established and patients completed 16 months safety f-up and response assessments. it
    is considered of limited value to follow patients for 3 years.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with locoregionally advanced squamous cell carcinoma of the oral cavity,
             oropharynx, hypopharynx or larynx

        Exclusion Criteria:

          -  Prior treatment with radiotherapy in the head and neck area

          -  Prior treatment with chemotherapy

          -  Prior treatment with similar drugs (e.g. EGFr antibodies, EGFr inhibitors)

          -  Previous surgery with curative intent for head and neck cancer
Clinical trial NCT00516542 (phase 1, status: terminated)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: letrozole, dhea
SMILES: N#CC1=CC=C(C=C1)C(N1C=NC=N1)C1=CC=C(C=C1)C#N, [H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C
Reason stopped: 
    study was terminated due to lack of accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of breast cancer

               -  Metastatic disease

          -  Hormone receptor status

               -  Estrogen receptor- and progesterone receptor-negative

               -  Androgen receptor-positive

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-3

          -  Postmenopausal (> 60 years of age)

          -  Leukocyte count > 3,000/uL

          -  Absolute neutrophil count > 1,500/uL

          -  Platelet count > 100,000/uL

          -  Total bilirubin normal

          -  AST and ALT < 2.5 times upper limit of normal

          -  Creatinine normal OR creatinine clearance > 60 mL/min

        PRIOR CONCURRENT THERAPY:

          -  At least 4 weeks since prior chemotherapy

          -  At least 4 weeks since prior biologic therapy

          -  At least 4 weeks since prior radiotherapy

          -  At least 30 days since prior investigational agents

          -  No concurrent dehydroepiandrosterone or androstenedione supplements

          -  No concurrent chemotherapy or radiotherapy

          -  No concurrent hormone therapy or immunotherapy (including trastuzumab [Herceptin®])
Clinical trial NCT00574912 (phase 1, status: completed)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: placebo, insulin glargine 0.5 u/kg body wt sc, insulin glargine 1.0 u/kg body wt sc, insulin glargine 1.5 u/kg body wt sc, insulin glargine 2.0 u/kg body wt sc
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  12 adults (males or females) with type 2 diabetes for at least six (6) months. May be
             using oral agents (SUs, metformin, acarbose or glitinides) with or without insulin.

          -  HgbA1c 7 -12%

          -  Age 18-70 years

          -  BMI 27-40 kg/m²

        Exclusion Criteria:

          -  Any past or present clinically relevant abnormality, medical condition, or
             circumstance making the subject unsuitable for participation in the study

          -  Evidence of hepatic, renal or cardiac failure

          -  Abnormal results following screening tests

          -  Pregnant or lactating females or females of childbearing potential who are unwilling
             to abstain from sexual intercourse or use reliable, medically accepted methods of
             contraception

          -  Currently using TZDs

          -  History of alcoholism or drug abuse within 12 months of the study
Clinical trial NCT01317797 (phase 1, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: namilumab (mt203), placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Out-patients with active rheumatoid arthritis (RA), according to the ACR 1987 revised
             criteria, with low to moderate disease activity (DAS28-ESR ≥ 2.6 and ≤ 5.1)

          2. Patients must be on stable doses of methotrexate (MTX) ≥ 7.5 and ≤ 25 mg/week for at
             least 12 weeks before the first injection, with appropriate folic acid supplementation

          3. Age ≥ 18 years at Screening

          4. Body weight at least 50 kg at Screening; BMI: ≥ 18.0 and ≤ 30.0 kg/m2 at Screening

          5. Negative tuberculosis test at Screening

          6. Heterosexually active male and female patients of childbearing potential are obliged
             to follow whatever contraceptive and / or breastfeeding restrictions may be required
             for their concomitant medication(s), including methotrexate.

        In addition, heterosexually active male and female patients of childbearing potential are
        required to use effective double-method contraception (one hormonal contraceptive or
        intrauterine device and one other additional contraceptive method) for 1 month before the
        first administration of the IMP, during the course of the trial, and for 6 month after the
        last injection of MT203.

        No special requirements are made for female patients proven to be post-menopausal (at least
        2 years after last menstrual period and FSH ≥ 40IU/L), surgically sterilized or
        hysterectomized. Likewise no special requirements for heterosexually active male who are
        surgical sterilized.

        Pregnant or lactating female patients have to be excluded.

        Exclusion Criteria:

          1. Participation in another clinical trial or previous dosing in this trial

          2. Use of specified medications within certain timeframes or use of certain comedications

          3. History or presence of specified diseases

          4. Drug abuse

          5. Certain laboratory parameters outside a specified range

          6. Donation of blood

          7. Relevant decrease in lung function

          8. Infections, frequent or chronic infections, herpes zoster

          9. Females: positive pregnancy test

         10. Presence of history of tuberculosis

         11. History of malignancy
Clinical trial NCT01763333 (phase 1, status: completed)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: bi 1026706 placebo, bi 1026706
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

        1. healthy male subjects

        Exclusion criteria:

        1. Any relevant deviation from healthy conditions
Clinical trial NCT01123824 (phase 1, status: completed)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: clopidogrel, placebo
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

        Healthy subject in good health, as determined by a medical history, physical examination
        including vital signs and clinical laboratory tests:

          -  with a body weight between 45 kg and 95 kg if male, between 40 kg and 85 kg if female,
             and with a Body Mass Index (BMI) between 18 and 30 kg/m²

          -  classified into one of the 4 groups of metabolizers according to his/her CYP2C19
             genotype:

               -  Ultrarapid Metabolizers (UMs, CYP2C19*1/*17 and CYP2C19*17/*17)

               -  homozygous Extensive Metabolizers (homoEMs, CYP2C19*1/*1)

               -  heterozygous Extensive Metabolizers (heteroEMs, CYP2C19*1/*2 and CYP2C19*1/*3)

               -  Poor Metabolizers (PMs, CYP2C19*2/*2 and CYP2C19*2/*3)

        Exclusion criteria:

          -  Evidence of inherited disorder of coagulation/hemostasis functions

          -  Subject smoking more than 10 cigarettes or equivalent per day

          -  Unability to abstain from intake of any drug affecting hemostasis throughout the whole
             study duration

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT01629849 (phase 1, status: completed)
Conditions: healthy, asthma
ICD codes: Z76.3, Z76.2, J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: placebo to bi 1021958 qd, bi 1021958 bid, placebo to bi 1021958 bid, bi 1021958 qd
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

        1. Healthy male and female subjects ofn non child-bearing potential

        Exclusion criteria:

        1. Any relevant deviation from healthy conditions except mild controlled asthma
Clinical trial NCT00530309 (phase 1, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: gsk716155 for injection, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          -  Type 2 diabetes mellitus diagnosed at least 3 months with FPG level <=240mg/dL and
             HbA1c between 6.5% and 10% inclusive.

          -  Must be diet controlled - OR - taking a single oral antidiabetic agent (other than
             thiazolidinediones) and willing to withdraw from this treatment from 2 weeks prior to
             the study.

          -  Must have a BMI:<=35kg/m2, 20 to 70 years of age inclusive.

          -  Woman must be of non-childbearing potential.

        Exclusion criteria:

          -  Positive test result for either syphilis, HBs antigen, HCV antibody, HIV
             antigen/antibody, or HTLV-1 antibody.

          -  Clinically significant hepatic enzyme elevation.

          -  History of metabolic disease other than T2DM.

          -  Previous use of insulin as a treatment for diabetes within 3 months.

          -  History of severe gastrointestinal disease.

          -  Clinically significant cardiovascular disease.

          -  Significant renal disease as defined by screening lab test.

          -  History of drug (including albumin or albumin containing agents) allergy.

          -  History of alcohol or drug abuse.

          -  Donation of blood in excess of 400mL within previous 4 months.

          -  Previously received any GLP-1 mimetic or any other albumin-containing products.
Clinical trial NCT00600964 (phase 1, status: completed)
Conditions: chronic lymphocytic leukemia
ICD codes: C91.11, C91.12, C91.10
Drugs: gx15-070ms, gx15-070ms
SMILES: COC1=CC(=N\C1=C/C1=C(C)C=C(C)N1)C1=CC2=CC=CC=C2N1, COC1=CC(=N\C1=C/C1=C(C)C=C(C)N1)C1=CC2=CC=CC=C2N1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed B-CLL

          -  Previous standard systemic chemotherapy, including fludarabine. There are no
             limitations on additional, allowable type and amount of prior therapy. Acute
             toxicities from prior therapy must have resolved to ≤Grade 1

          -  Age ≥18 years

          -  ECOG Performance Status ≤1

          -  Life expectancy of >8 weeks

        Exclusion Criteria:

          -  Patients receiving any other investigational agents (e.g., under another IND) or
             commercial agents or therapies administered with the intent to treat their malignancy

          -  Patients with history of seizure disorders

          -  Pregnant women and women who are breast feeding

          -  HIV-positive patients receiving combination anti-retroviral therapy
Clinical trial NCT00542958 (phase 1, status: completed)
Conditions: cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: nk012
SMILES: CCC1=C2C=C(O)C=CC2=NC2=C1CN1C2=CC2=C(COC(=O)[C@]2(O)CC)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed malignant solid tumor for which there are no known regimens
             or protocol treatments of higher efficacy or priority

          -  Failed conventional therapy for the cancer or have a malignancy for which a
             conventional therapy does not exist

          -  Recovered from all acute adverse effects of prior therapies, excluding alopecia (hair
             loss)

          -  Life expectancy of at least 12 weeks and an EOCG performance status of 0 or 1

          -  18 years of age or older

          -  Adequate kidney, liver, and bone marrow function

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or
             mitomycin C) prior to entering the study or have not recovered from adverse effects
             due to agents administered more than 4 weeks earlier

          -  Receiving any other investigational agent

          -  History of brain metastases or spinal cord compression, unless irradiated a minimum of
             4 weeks before study entry and stable without requirement for corticosteroids for > 1
             week

          -  History of allergic reactions attributed to compounds of similar chemical composition
             to NK012

          -  Concurrent serious infections (i.e., requiring an intravenous antibiotic)

          -  Pregnant women or women of childbearing potential who are not using methods to avoid
             pregnancy; a negative pregnancy test (urine or serum) must be documented at baseline
             and before every NK012 administration for women of childbearing potential; no
             breast-feeding while on study

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, unstable angina pectoris or psychiatric illness/social situations that
             would limit compliance with study requirements

          -  Significant cardiac disease

          -  History of serious ventricular arrhythmia

          -  Positive for anti-HbsAg, anti-HCV, anti-HIV, or anti-syphilis antibodies
Clinical trial NCT00162214 (phase 1, status: terminated)
Conditions: tumors
ICD codes: E88.3, R97.8, C49.A0, C49.A1, C49.A2, C49.A5, C49.A3
Drugs: dasatinib + ketoconazole
SMILES: CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
Eligibility criteria:

        Inclusion Criteria:

          -  ECOG status 0-2

          -  Advanced or metastatic disease, unresponsive to standard treatment (or no standard
             treatment exists)

          -  Biopsy pretreatment

          -  Adequate bone marrow, liver and kidney function

        Exclusion Criteria:

          -  Serious cardiovascular disease

          -  Bleeding disorders

          -  Gastrointestinal (GI) tract disease

          -  Platelet inhibitors

          -  H2 blockers, proton pump inhibitors
Clinical trial NCT00623012 (phase 1/phase 2, status: terminated)
Conditions: graft versus host disease
ICD codes: D89.810, D89.811, D89.813, D89.812
Drugs: rapamycin, tacrolimus
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC, COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O
Reason stopped: 
    low accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Age ≥18 years

          -  Received an allogeneic MSD or MUD PBSCT

          -  24 weeks post SCT

          -  Currently on Tacrolimus for GVHD prophylaxis

          -  Deemed eligible for tapering off of Tacrolimus by primary BMT physician

        Exclusion Criteria:

          -  Relapsed Disease

          -  Ongoing GVHD

          -  Patients whose immunosuppression is being stopped early to treat or prevent relapse

          -  Patients with pure red cell aplasia due to ABO mismatched donor

          -  Ongoing thrombotic microangiopathy

          -  Allergy to rapamycin

          -  Women of childbearing potential must have a negative serum pregnancy test performed
             prior to the start of treatment